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Abstract
We experimentally monitored, at the single-molecule level, the competition among reverse
transcription, exponential amplification (RT-LAMP), and linear degradation (restriction enzymes)
starting with Hepatitis C viral RNA molecules. We found significant heterogeneity in the rate of
single-molecule amplification; introduction of the restriction enzymes affected both the rate and
the “fate” (the binary outcome) of single-molecule amplification. While end-point digital
measurements were primarily sensitive to changes in fate, the bulk real-time kinetic measurements
were dominated by the rate of amplification of the earliest molecules, and not sensitive to fate of
the rest of the molecules. We showed how this competition of reactions can be used for rapid
HCV genotyping with either digital or bulk readout. This work advances our understanding of
single-molecule dynamics in reaction networks and may help bring genotyping capabilities out of
clinical labs and into limited-resource settings.
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This paper presents single-molecule kinetic measurements of how the competition between
exponential amplification of RNA molecules and their linear degradation affects both the
“rate” and “fate” of amplification, and shows how such competition can be used to design
assays for rapid genotyping of the hepatitis C virus.
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A wide range of diagnostic solutions for global health are urgently needed,[1] including for
HCV, which infects 130-170 million people worldwide.[2] These patients can now be treated
with recently approved small-molecule drugs,[3] which replace or reduce interferon therapy,
but genotyping is still required to determine the treatment each patient should receive.
However, most of these patients or their primary care doctors are located in limited-resource
settings. High-complexity molecular tests such as commercially available HCV genotyping
assays are not well suited for such settings (see SI). Therefore, a rapid (<1 hr), robust, and
simple system for genotyping remains an unmet need. HCV genotypes differ by sets of
mutations, with overlap between sequences of some but not all genotypes. Instead of
attempting to design a separate detection reaction for each genotype, we wished to test
whether we could design a competition reaction network (Figure 1): the detection for
multiple HCV genotypes takes place in a single core amplification reaction, and the
specificity for genotypes is achieved by the competing sequence-specific inhibition
reactions.
The use of competition among reactions to achieve regulation is common in biological
systems; in our personal favorite example of the blood coagulation cascade,[4] the core
autocatalytic amplification cascade is held in check by multiple inhibitors. Here, we wished
to use a competition system consisting of reverse transcription loop-mediated isothermal
amplification (RT-LAMP) as the amplification reaction, and restriction enzyme (RE)
digestion as the inhibition reaction. Single-molecule, or “digital”[5] LAMP[6] is attractive for
quantification under limited-resource settings due to its high intensity fluorescent output
with calcein chemistry.[7] Digital RT-LAMP for the quantification of human
immunodeficiency virus RNA was shown to be robust to perturbations in reaction
conditions, imaging, temperature, and automatic cloud-based analysis, enabling robust cell
phone–based quantification.[7b] In this work, we used RT-LAMP primers (see Table S1 in
Supporting Information (SI)) modified from previous work targeting the conserved 5′-
untranslated region (5′UTR) of HCV.[8] RE-based digestion is a reliable method to
recognize specific nucleic acid sequences of multiple letters in length and cleave at specific
sites.[9] We hypothesized that RE digestion could be used to compete with RT-LAMP
amplification in situ in both bulk and digital formats.
Although the kinetics of single-molecule amplification has been studied for some reactions
such as enzymatic turnover of a substrate [5b] or digital PCR,[5a] it has not been studied for
sequence-specific isothermal amplification reactions, especially when competing reactions
are involved. Therefore, before we could test this idea, we first had to answer three
fundamental questions: i) How significant is the heterogeneity in the rate of digital RT-
LAMP amplification? We expected some heterogeneity because LAMP itself has a complex
mechanism, and RT-LAMP introduces an additional reverse transcription step from RNA
molecules with heavy secondary structures. ii) Would introduction of RE affect the rate, or
the fate, of digital RT-LAMP amplification (Figure 2A)? For simplicity, here we defined
“rate” as the inverse of the “time-to-positive,” or time it takes the amplification to produce a
particular level of a signal; competition from RE could decrease the rate of amplification by
consuming some of the amplification products. We defined “fate” as whether or not
amplification ultimately succeeds to provide that level of signal from a single molecule. For
example, in the RT-LAMP/RE mechanism (Figure 2B), one fate-determining step could
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occur once the first double-stranded DNA (dsDNA) is formed (structure (1) in Figure 2B):
either RE can bind to the strand and cleave it, or primer annealing followed by polymerase
binding could lead to the formation of the double-looped template that can be further
amplified. Such stochastic fate determination could also occur elsewhere during the early
stages of the reaction as long as the number of molecules remains small. iii) Would this
competition affect the bulk reaction differently from the single-molecule reactions? Given
that this reaction system has significant nonlinearity, it is predicted[10] to be affected by the
spatial distribution and compartmentalization.
To answer the first two questions, we performed real-time digital RT-LAMP/RE
experiments with HCV genotype 1 (GT1) RNA and BsrBI as the RE. HCV GT1 isolate was
obtained commercially and sequenced after RNA purification to confirm the genotype
assignment (Table S2 in SI). BsrBI cuts dsDNA at sequences CCGCTC, and this sequence
exists in the RT-LAMP amplicon of GT1 RNA. With negative control experiments, we
identified the highest possible BsrBI concentration that did not trigger ab initio DNA
synthesis within the time of interest under reaction conditions (Figure S1 in SI).[11] The
concentration was determined by performing a RE dilution experiment in the presence of all
RT-LAMP components except HCV RNA and choosing the concentration for which ab
initio synthesis was not observed within 50 min. We used a SlipChip microfluidic device
(Figure S2 in SI) modified based on previous publication[6b] to compartmentalize the
reaction mixture and monitored the progress of amplification for each single molecule using
a CCD-based imaging system (Figure 3). Even in the amplification reaction in the absence
of the RE, we found significant heterogeneity among rates of amplification of different
molecules (Figure 3A). Addition of BsrBI did not abolish this heterogeneity (Figure 3B). On
average, even though the rates of the reactions decreased upon addition of BsrBI, the shift in
reaction times (approximately 5 min, for the first well that turned positive) was small
relative to the width of the distribution of the reaction times (over 30 min). On the other
hand, the fate of single-molecule amplification did change significantly upon addition of
BsrBI: ~10-fold fewer molecules gave rise to successful amplification (with a p-value of
0.00033), indicating that in digital RT-LAMP, BsrBI affects fate more than it affects rate.
To answer the third question, we performed the same competition experiments in the bulk
real-time format using an RNA concentration of ~3.3×105 copies/mL (estimated based on
digital RT-LAMP results), equivalent to the concentration of a single molecule in a 3 nL
well. Without BsrBI, the reaction in this bulk experiment was approximately 5 min faster
than the mean amplification time in the corresponding digital experiment (Figure 3A); it was
closer to the time of the amplification of the first molecule (approximately 2 min slower)
(Figure 3C). Upon addition of BsrBI, the bulk reaction showed increased variance and
slowed down by Δtb = 4.9 ±1.9 min (Figure 3C); this delay was similar to the delay of the
time-to-positive of the first molecule in the digital format, Δtd = 4.2 ± 1.1 min (Figure 3C).
These data suggest that once exponential amplification of some molecules takes off, this
process dominates the reaction mixture and is not affected by the amplification of the
molecules that amplify later in the digital format—the bulk reaction has ended by then. In
other words, the bulk experiment is dominated by the rate of amplification of the earliest
molecules, and not sensitive to the fate of the rest of the molecules. We then tested if this
concept could be applied to perform HCV genotyping. Our goal was not to validate a
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genotyping assay with a broad panel of clinical samples from across the globe. Instead, we
wished to understand whether a proof-of-concept experiment was possible, and therefore we
focused on HCV samples of the four most common genotypes in the USA[12] which were
readily available to us from commercial sources (see Experimental section in SI).
Sequencing results of the 5′UTR of these samples confirmed their genotype
assignment(Table S2 in SI). Based on consensus obtained by aligning sequences of each
genotype obtained from LANL[13], three REs thermostable under RT-LAMP conditions
were chosen to target the sequence differences between these four genotypes within the RT-
LAMP amplicon. NheI-HF (targeting GCTAGC) should recognize genotypes 1, 2, and 4;
BsrBI (targeting CCGCTC) should recognize genotypes 1, 3, and 4; and BstNI (targeting
CCWGG) should recognize only GT1 (Figure 4A). We have confirmed that under LAMP
conditions these three enzymes remained active and sequence specific (Figure S3 in SI);
such tests should be performed if additional REs are included. Because one RE can probe
multiple genotypes, in principle unambiguous genotyping panels can be designed with fewer
reactions than genotypes (e.g., three REs to differentiate four genotypes here). We note that
this approach is well-suited for probing multiple mutations within the same amplification
region; alternatively, several amplification reactions can compete with several cleavage
reactions for higher multiplicity.
For each genotype, we performed four digital experiments: one positive control without RE,
and three experiments with one RE each. The positive control also provided a measurement
of the viral load and validation for performing digital experiments (see Table S3 in SI). The
experimental results (Figure 4B) agreed with the inhibition pattern predicted (Figure 4A).
Amplification of GT1 was inhibited by all three REs; amplification of GT2 was inhibited by
NheI-HF only; amplification of GT3 was inhibited by BsrBI; and amplification of GT4 was
inhibited by NheI-HF and BsrBI. The fate of molecules for each combination was dependent
somewhat on the RE being used, but in all cases the inhibition was strong and statistically
significant (Figure 5B).
We then compared the performance of this HCV genotyping approach in a digital format to
that in a real-time bulk format (Figure 5). Experimental repeats were performed on different
days to ensure these experiments were not merely technical replicates. Both formats agreed
with the prediction shown in Figure 4A. In the digital format (Figure 5B), reactions with RE
specific to the genotype showed reduced counts by at least 10 fold, giving statistically
significant results (p < 0.022). In the bulk format (Figure 5A), reactions with RE that are
specific to the genotype were all delayed by a certain amount of time ranging from 2 min
(~10% relative to time-to-positive of positive control) to 20 min (~100% relative to time-to-
positive of positive control). Acceptable p-values were obtained for three of the four
genotypes (p = 0.079 for GT2 and p < 0.032 for others). As the strength of inhibition by the
RE increased, (e.g., NheI-HF in Figure 5B), in digital, lower counts and smaller p-values
were observed. Paradoxically, stronger inhibition by RE in real-time bulk experiments led to
a larger variation of reaction times and therefore did not improve p-values. Presumably,
strong inhibition brings bulk amplification into the stochastic regime; this connection
between digital “fate” and bulk “rate” deserves to be investigated further.
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Here, we performed real-time kinetic measurements of competition between two reactions at
the single-molecule level, and found that this competition affects both the rate and fate of
single-molecule amplification. We observed significant heterogeneity in the rate of
amplification of individual molecules, both in RT-LAMP amplification of HCV RNA, and
in its competition with REs. We found that the introduction of the RE impacts both the rate
and the fate of single-molecule amplification. We found a difference in how this competition
is reflected in the readouts we used. Both fate and rate can be measured with real-time
digital experiments. End-point digital experiments ignore the rate and measure fate, while
bulk real-time experiments ignore the fate and rate of the majority of molecules and instead
measure the rate and fate of the early amplification events. We demonstrated that both of
these simplified measurements could in principle be used to derive genotype information
from the competition of amplification and RE digestion. The advantage of the real-time
methodology is that it is well-established and does not require development of microfluidic
devices. We, however, prefer the end-point digital format for limited-resource settings: it
does not require complex instrumentation for performing kinetic measurements; it is
expected to be robust to fluctuation in conditions (although this robustness remains to be
studied for competition reactions);[7b, 14] and it can be read-out with a cell phone,[1a, 7b]
which we confirmed here as well (Figure S6 in SI). Although not described here, research is
underway to integrate this method with user-friendly sample preparation techniques to
enable full deployment in limited-resource settings. Further, the end-point digital format
gives viral load information directly in the control—although, while digital amplification is
often claimed to provide absolute concentration, determining the true concentration of
molecules requires carefully measuring and adjusting for the efficiency of the processing
and amplification, which we have not investigated in this manuscript. For genotyping,
absolute measurements are not required, as only the magnitude of the decrease of digital
counts upon introduction of the RE needs to be measured, which essentially sets the
requirement for resolution of the platform used. For a specific digital device, resolution and
dynamic range (i.e., the range of viral concentrations over which the genotyping
measurement can be reliably performed on a given device) are in balance with one another
—the lower the requirement for resolution, the larger dynamic range it has. For example, in
a published multivolume SlipChip[15] device, the dynamic range for 5-fold resolution is 67
to 2×107 copies/ mL. In this RT-LAMP/RE system, the requirement for resolution is only 10
fold and a better inhibition chemistry would further lower the required resolution, and
increase the dynamic range, of the digital measurement. The results presented in this paper
raise a number of additional questions: What is the right theoretical framework within which
to analyze both rate and fate in single-molecule competition reactions? What are the
molecular details of the mechanisms responsible for fate and rate determination in such
systems? Can robustness of output of these systems be predicted a priori? What are the best
amplification and inhibition chemistries with which to implement such competition
reactions for genotyping and other genetic analyses?
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Schematic of a network based on competition between amplification (solid black lines and
arrow) and inhibition (solid red). Any one of four HCV genotypes could be independently
amplified by one RT-LAMP reaction and inhibited specifically by different restriction
digestion reactions. When the restriction enzyme (RE) is specific to that genotype, it
produces an inhibition feedback to the amplification (solid red). When the RE is not specific
to the genotype, there is no inhibition even in the presence of RE (dashed black).
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Figure 2.
Schematic overview of the definition of “fate” and “rate” in general (a) and specifically for
the competition between RT See text for details.
Sun et al. Page 8
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2015 July 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Results of real-time, single-molecule digital RT-LAMP/RE experiments for HCV RNA. (a),
(b) Graphs showing 1280 fluorescence traces for the RT-LAMP amplification process of all
the wells on a SlipChip device (solid light blue) and normalized averaged fluorescence curve
in bulk (dashed dark blue) in the absence of RE (a) and the traces for digital (solid light red)
and for bulk (dashed dark red) in the presence of RE BsrBI (b) (see Figure S4 in SI for bulk
data details). Horizontal solid lines indicate the threshold levels to consider a well positive.
Vertical solid lines show the mean of the time-to-positive distribution. The scales in (a) and
(b) are the same. (c) Graph showing the change of cumulative counts over time for wells
exceeding the threshold in (a), blue, and (b), red (see Figure S5 in SI for histogram over
time). The two bars below the x-axis show time-to-positive for real-time bulk experiments,
the widths of which stand for standard deviation for the bulk assay (n=5).
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Figure 4.
(a) Predicted HCV genotyping pattern based on REs used and (b) photographs (inverted
intensity) of end-point digital experimental genotyping results (only a part of each chip is
shown). The first column in both sections represents the positive control in the absence of
RE and the following three columns indicate experiments with different REs. Each row
represents a genotype (GT) of HCV RNA. Red frame indicates predicted inhibition.
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Figure 5.
Graphs showing a comparison of HCV genotyping results using (a) real-time bulk assay (ttp:
time-to-positive) and (b) end-point digital assay (n=3).
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